



NOTICE: RECOMMENDED THERAPEUTIC ALTERNATIVE FOR DESMOPRESSIN NASAL FORMULATIONS

The Paediatric Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) (2017 edition) and, the Adult Hospital Level STGs and EML (2019 edition) recommend the use of desmopressin nasal spray in the specialist management of central diabetes insipidus.

The Desmopressin; 100mcg/ml; Spray, Nasal; 5 ml product on contract *HP07-2020DAI: Supply and Delivery of Pharmaceutical products: Drops, Aerosols and Inhaled Medicines to the Department of Health for the Period 1 July 2020 to 30 June 2023*, has been recalled and will likely only be available in 2022. Desmopressin nasal solution is also currently not available as an alternative.

The following therapeutic alternatives are recommended for the use of desmopressin nasal spray in the management of central diabetes insipidus:

Indications: Paediatric Hospital Level (2017)	Current recommendation in STGs and EML	Therapeutic alternative
<ul style="list-style-type: none"> 7.4 Diabetes insipidus (In infants or where oral administration is not feasible) 	<p>Infants or where oral administration is not feasible:</p> <ul style="list-style-type: none"> Desmopressin, nasal spray, 10 mcg/day (0.1 mL), starting dose. <ul style="list-style-type: none"> Titrate according to response. Use the lowest dose at which an antidiuretic effect is obtained. Maximum daily dose: 30 mcg/day once or twice daily. 	<ul style="list-style-type: none"> Desmopressin, oral, 0.1mg/day starting dose in 3 divided doses <ul style="list-style-type: none"> Crush 0.1 mg tablets and suspend in water, administer in 3 divided doses per day. Titrate according to response. <p><i>Doses to be initiated and titrated by a specialist.</i></p>
Indications: Adult Hospital Level (2019)	Current recommendation in STGs and EML	Therapeutic alternative
<ul style="list-style-type: none"> 8.15.3 Diabetes Insipidus Postoperative or acutely ill patients 	<ul style="list-style-type: none"> Desmopressin, IV/SC, 2–4 mcg daily, either as a single dose or in 2 divided doses. <p>OR</p> <ul style="list-style-type: none"> Desmopressin, nasal spray, 10–40 mcg daily, either as a single dose or in 2–3 divided doses. <p>OR</p> <ul style="list-style-type: none"> Desmopressin, oral, 0.05 mg, 8–12 hourly. <ul style="list-style-type: none"> Optimal dose: 0.1–0.8 mg daily. Adjust dose according to response to a maximum of 1.2 mg daily in divided doses. 	<ul style="list-style-type: none"> Desmopressin, IV/SC, 2–4 mcg daily, either as a single dose or in 2 divided doses. <p>OR</p> <ul style="list-style-type: none"> Desmopressin, oral, 0.05 mg, 8–12 hourly. <ul style="list-style-type: none"> Optimal dose: 0.1–0.8 mg daily. Adjust dose according to response to a maximum of 1.2 mg daily in divided doses.

<ul style="list-style-type: none"> • 8.15.3 Diabetes Insipidus <i>Replacement therapy</i> 	<ul style="list-style-type: none"> • Desmopressin, nasal spray, 10–40 mcg daily, either as a single dose or in 2–3 divided doses. <ul style="list-style-type: none"> ○ Adjust morning and evening doses separately for appropriate diurnal rhythm of water turnover. OR • Desmopressin, oral, 0.05 mg, either as a single dose or in 2–3 divided doses. <ul style="list-style-type: none"> ○ Optimal dose: 0.1–0.8 mg daily. ○ Adjust dose according to response to a maximum of 1.2 mg daily in divided doses. 	<ul style="list-style-type: none"> • Desmopressin, oral, 0.05 mg, either as a single dose or in 2–3 divided doses. <ul style="list-style-type: none"> ○ Optimal dose: 0.1–0.8 mg daily. ○ Adjust dose according to response to a maximum of 1.2 mg daily in divided doses.
---	--	--

**Note: Dosing of oral and nasal desmopressin formulations are different owing to the difference in absorption rates.*

Provinces and Healthcare Facilities are requested to distribute and communicate this information in consultation with the Pharmaceutical and Therapeutics Committees.

Kindly share with all healthcare professional and relevant stakeholders.

Comments may be submitted via e-mail:

Stock queries:

Ms Babalwa Melitafa


E-mail: Babalwa.Melitafa@health.gov.za

Clinical queries:

Essential Drugs Programme

E-mail: SAEDP@health.gov.za

Kind regards



MS K JAMALOODIEN

DIRECTOR: AFFORDABLE MEDICINES

DATE: 26 November 2020